Renaissance Technologies’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Renaissance Technologies’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-238,133	Closed	-$62K	–	4458
2023 Q1	$62K	Buy	238,133 +172,800	+264%	+$50.5K	﹤0.01%	3612
2022 Q4	$14K	Buy	65,333 +39,500	+153%	+$9.88K	﹤0.01%	4017
2022 Q3	$7K	Buy	25,833 +13,200	+104%	+$6.16K	﹤0.01%	3965
2022 Q2	$9K	Buy	+12,633	New	+$10.7K	﹤0.01%	4165
2021 Q2	–	Sell	-131,618	Closed	-$266K	–	3947
2021 Q1	$266K	Buy	131,618 +75,923	+136%	+$178K	﹤0.01%	3088
2020 Q4	$120K	Sell	55,695 -40,453	-42%	-$95.4K	﹤0.01%	3236
2020 Q3	$260K	Sell	96,148 -152,852	-61%	-$548K	﹤0.01%	3043
2020 Q2	$981K	Buy	+249,000	New	+$476K	﹤0.01%	2547
2016 Q1	–	Sell	-30,330	Closed	-$807K	–	3625
2015 Q4	$807K	Buy	30,330 +8,380	+38%	+$291K	﹤0.01%	2558
2015 Q3	$1M	Buy	+21,950	New	+$828K	﹤0.01%	2383
2015 Q2	–	Sell	-775	Closed	-$25K	–	3476
2015 Q1	$25K	Buy	+775	New	+$26.2K	﹤0.01%	3112

Other funds holding NAVB

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PFO

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Renaissance Technologies's NAVB Position: Q2 2023 in Review

Renaissance Technologies sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 238,133 shares — an estimated $62K sold.

Renaissance Technologies first reported a position in NAVB in Q1 2015 and held it in 11 quarters. The position peaked at $1M in Q3 2015. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

Renaissance Technologies reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 238,133 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $62K.
Renaissance Technologies first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2015 and held it in 11 quarters.
Renaissance Technologies's Navidea Biopharmaceuticals Inc. position peaked at $1M in Q3 2015.
23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.